Skip to main content
Evidence Snapshot

Coagulation factor X

CHEMBL244 SINGLE PROTEIN Homo sapiens
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:04Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL244
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Coagulation factor X as ChEMBL target CHEMBL244, mapped to UniProt P00742. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Coagulation factor X
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL244
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P00742
Coagulation factor X
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Coagulation factor X matters

As of 2026-09-13

Coagulation factor X is reviewed as Coagulation factor X (UniProt P00742); Coagulation factor X shows approved-linked disease relevance led by atrial fibrillation. 5 more disease programs remain visible in the same review block.; 7 linked drugs keep this evidence frame grounded.; the current evidence base includes 14 approved drugs, 7669 compounds, and 736 assays, with lead potency reaching pChEMBL 11.0.

Disease context
atrial fibrillation

Coagulation factor X shows approved-linked disease relevance led by atrial fibrillation. 5 more disease programs remain visible in the same review block. 7 linked drugs keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include APIXABAN, BETRIXABAN, DAREXABAN.

Start review with atrial fibrillation because it currently carries approved-linked support. Linked drugs include APIXABAN, BETRIXABAN, DAREXABAN, EDOXABAN TOSYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Approved-linked 7 linked drugs
Activity base
Portfolio and assay base

ChEMBL currently tracks 14 approved drugs, 7669 compounds, and 736 assays for this target. The dominant activity type is KI. CHEMBL507020 is the current potency anchor at pChEMBL 11.0.

Use CHEMBL507020 as the tractability anchor when discussing potency (pChEMBL 11.0).

Activity source · ChEMBL 36 via Core Engine
14 approved pChEMBL 11.0
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Coagulation factor X matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt P00742, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need to see why atrial fibrillation is currently treated as approved-linked support.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

7669
Total Compounds
736
Total Assays
14
Approved Drugs
IC50: 3823.0, KI: 4761.0, KD: 97.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL507020
 11.0 IC50 —
No preferred name
CHEMBL152859
 11.0 Ki —
No preferred name
CHEMBL37251
 11.0 Ki —
No preferred name
CHEMBL174330
 10.9 Ki —
No preferred name
CHEMBL387856
 10.9 Ki —

Approved Drugs

Structure Compound First Approval
BETRIXABAN
CHEMBL512351
 2017
EDOXABAN
CHEMBL1269025
 2015
APIXABAN
CHEMBL231779
 2011
RIVAROXABAN
CHEMBL198362
 2008
FONDAPARINUX SODIUM
CHEMBL1200644
 2001
FONDAPARINUX
CHEMBL1201202
 2001
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:04Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL244